Health Care

Eli Lilly’s Q1 earnings will reveal if Foundayo’s slow GLP‑1 adoption and its $7 billion Kelonia CAR‑T deal can sustain growth and diversify revenue in 2024.

ResMed Inc’s recent dip reflects a broader healthcare pullback, not company woes. Learn how sector trends, regulatory shifts, and digital health drive investor risk.

Merck’s share dip amid a tech rally shows pharma’s slower momentum; insights on its vaccine tie‑ups, R&D spend and precision‑medicine prospects guide investors.

HCA Healthcare’s share slump reflects sector headwinds and earnings gaps—examining margin dips, debt rise, and tech adoption for a clearer path to resilience.

Explore Daiichi Sankyo’s Q1 2026 earnings: 5.5 % revenue lift, 3.3 % EPS rise, and strategic gains amid Japan’s value‑based drug pricing.

Novartis pulls EU filing for Pluvicto’s expanded prostate‑cancer indication, sparking market, HTA and reimbursement shifts while keeping global growth and pipeline focus strong.

Zoetis’ share slump hits a record low as investors fear its osteoarthritis therapy’s regulatory and safety hurdles.

Sanofi’s €2.3 bn EMTN boost: low‑rate, medium‑term debt to fuel AI‑driven drugs, digital health and ESG projects while cushioning rate hikes and geopolitical risks.

Regeneron’s gene‑therapy REG‑HL1 earns FDA accelerated approval, offering free treatment for rare congenital hearing loss and setting a new standard for equitable, outcome‑based pricing in gene‑therapy development.

Edwards Lifesciences Q1 2026 earnings show modest EPS growth and a 7.3 % revenue rise driven by valve sales and a critical‑care rebound.